According to the World Health Organization, TB is responsible for over one million annual deaths Researchers from the National Institute for Health and Care Research’s (NIHR) Southampton Biomedical Research Centre have identified a group of biological markers of tuberculosis (TB) found in high levels among infected patients. Published in the Journal of Clinical Investigation Insight for World TB Day (24 March 2024), findings from the study could advance a simple blood test to speed up the diagnosis of the infection. According to the World Health Organization, TB is the world’s deadliest infectious disease, caused by a bacterium known as Mycobacterium tuberculosis, which is responsible for more than one million deaths each year. Estimated to affect ten million people globally every year, the highly contagious and easily transmitted TB spreads through the air when infected people cough, sneeze or spit, often affecting the lungs. Supported by the NIHR and the UK ...
Rare kidney diseases are a group of conditions which account for over 5% of people living with chronic kidney disease A new study led by University College London (UCL) and the UK Kidney Association has suggested that treatments for rare diseases could significantly reduce the burden of kidney disease for patients and the NHS. Published in The Lancet in alignment with World Kidney Day (14 March 2024), the study draws on the largest kidney disease dataset ever created, the UK’s National Registry of Rare Kidney Disease (RaDaR). Affecting over seven million adults, according to Kidney Research UK, chronic kidney disease (CKD) is characterised by the gradual loss of kidney function over a period of months to years. Rare kidney diseases such as cystinosis and Fabry disease are a group of conditions that affect less than one in 2,000 people, accounting for over 5% of people with CKD. Researchers charted the ...
The SOL3D pipeline addresses research challenges in relation to equipment, expertise and cost Scientists from King’s College London’s (KCL) UK Dementia Research Institute’s (UK DRI) have developed a process to enable custom cell culture device creation. Published at PLOS Biology, the soft-lithography on 3D vat polymerised (SOL3D) pipeline is cheaper, versatile, highly reproducible and modifies the microfabrication of cell culture devices to produce customised systems. Cell culture devices are designed to support physical environments for cells within the laboratory setting, enabling scientists to observe cell growth and how they interact with each other under different test conditions. Currently, wet labs use commercially developed microdevices, which are expensive and do not allow for customisation, ultimately narrowing the scope of research that can be done. The SOL3D pipeline, instead, offers the potential to create bespoke designs and addresses challenges in relation to equipment, expertise and cost. Researchers used bioengineering and microfabrication expertise ...
The annual meeting of the American Association for Cancer Research (AACR) will be held on April 5-10, 2024 local time in San Diego, USA. At the meeting, Yifang Bio will present the latest results from the Phase II clinical trial of garsorasib (D-1553) in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation. This will mark the study’s (NCT05383898) appearance at a prestigious international academic conference following the World Conference on Lung Cancer (WCLC) 2022. About Garsorasib KRAS mutations are widespread in several highly lethal cancer types, with KRAS G12C being a specific KRAS mutation that accounts for approximately 44% of all KRAS mutations.KRAS G12C mutations are more common in lung, colorectal, pancreatic, and bile duct cancers. According to Frost & Sullivan, from 2016 to 2020, the number of incidence of major KRAS G12C-mutated cancers in China increased from 38,000 to 43,000, and is expected to reach 58,000 ...
In the study, the Lymphoma Artificial Reader System accurately detected 90% of lymphatic cancersResearchers from Chalmers University of Technology in Sweden have developed a new computer model using artificial intelligence (AI), which successfully identifies signs of lymphatic cancer. The model was developed in collaboration with researchers from Memorial Sloan Kettering Cancer Center, Chalmers University of Technology, Medical University in Vienna, Icahn School of Medicine at Mount Sinai and NYU Langone Health, with results published in The Lancet Digital Health. Lymphoma is a cancer of the lymphatic system, including the lymph nodes, spleen, thymus gland and bone marrow, and can affect other organs throughout the body. The two main subtypes of lymphoma are Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, which is the sixth most common cancer in the UK, responsible for around 14,200 cases every year, according to Cancer Research UK. Using AI-assisted image analysis of lymphoma, researchers developed a deep learning ...
Affecting 55 million people globally, dementia impairs the ability to remember, think or make decisionsRoche and the Cardiff University Brain Research Imaging Centre (CUBRIC) have partnered to uncover new research to understand the structural changes of dementia. Using cutting-edge imaging and machine learning (ML), researchers will analyse the brains of patients living with Parkinson’s disease (PD) and Alzheimer’s disease (AD). Dementia is a general term used for the impaired ability to remember, think or make decisions that interferes with day-to-day activities and affects 55 million people globally, according to Alzheimer’s Society. Currently the most common form of dementia, AD is a progressive neurological disease that affects the part of the brain that controls thought, memory and language. PD is a progressive neurodegenerative disorder that affects the body’s nervous system. The main symptoms include shaking, slow movements and stiffness. The study will use advanced MRI to understand the bigger structural changes ...
Globally, cancer is currently the most leading cause of death due to disease among children The Institute of Cancer Research (ICR) has announced it has been selected to receive a Cancer Grand Challenges (CGC) award of up to $25m to research the challenges of solid tumours in children. First launched in 2020 by Cancer Research UK (CRUK) and the National Cancer Institute (NCI), CGC now brings together 1,200 researchers and 16 teams worldwide to take on 13 of “cancer’s toughest challenges”. Currently the leading cause of death due to disease among children globally, most outcomes for some childhood cancers have not improved in more than three decades. The CGC team PROTECT aims to explore new, less invasive and more targeted treatments for children living with cancers. For the next five years, the PROTECT team, involving experts from the ICR and the Hopp Children’s Cancer Center Heidelberg in Germany, will use ...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). These abstracts are now available on the AACR’s official website. The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting will be held from April 5-10 2024, in San Diego, California, USA. These three preclinical abstracts from Ascentage Pharma include: ...
Researchers from Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed an algorithm to identify high-risk precancerous lesions that lead to ovarian high-grade serous carcinoma (HGSC). Published in Clinical Cancer Research, researchers aimed to develop a tool that could detect and stratify serous tubal intraepithelial carcinomas (STICs) based on key genetic alterations and mutations. STICs are lesions that are presumed to be the main precursors of HGSC, the most common form of ovarian cancer in women. Using a technique called Repetitive Element AneupLoidy Sequencing System (RealSeqS), researchers sequenced 150 DNA samples and analysed the level of aneuploidy, missing or extra DNA chromosomes, in STIC versus HGSC and normal-appearing samples. Results showed that STIC samples had more non-random genetic alterations, including whole and partial deletions of chromosome 17 in the tumour suppressor p53 proteins, while normal-appearing samples had low levels of aneuploidy. The team suggests ...
The project will train a newly developed AI system on data collected from participating men and women Researchers from the University of Glasgow’s James Watt School of Engineering are aiming to ensure that artificial intelligence (AI)-based healthcare monitoring systems in the future are free of gender bias, to improve care for both men and women. For 18 months, the project will examine the potential for gender bias in healthcare AI and discover ways to ensure that AI-supported treatment remains equitable. The use of cutting-edge sensors is currently being investigated to track the rhythms of patients’ hearts and lungs without requiring them to wear monitoring devices or be recorded on video cameras. The team aims to address and ensure that its AI component is properly trained and capable of making the correct judgements without bias towards one gender of patients. Supported by £8,200 in funding from the Université Paris Dauphine-PSL’s Women ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.